Literature DB >> 24452361

Conjugation of vitamin E analog α-TOS to Pt(IV) complexes for dual-targeting anticancer therapy.

Kogularamanan Suntharalingam1, Ying Song, Stephen J Lippard.   

Abstract

We report two platinum(IV) complexes conjugated with a vitamin E analog, α-tocopherol succinate (α-TOS). One of the conjugates displays the activity of both cisplatin and α-TOS in cancer cells, causing damage to DNA and mitochondria simultaneously. Accordingly, it serves as a promising dual-targeting anticancer agent.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24452361      PMCID： PMC3938893          DOI： 10.1039/c3cc48740g

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  18 in total

1.  Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1.

Authors:  S T Smiley; M Reers; C Mottola-Hartshorn; M Lin; A Chen; T W Smith; G D Steele; L B Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

2.  DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139.

Authors:  E P Rogakou; D R Pilch; A H Orr; V S Ivanova; W M Bonner
Journal:  J Biol Chem       Date:  1998-03-06       Impact factor: 5.157

3.  alpha-tocopheryl succinate-induced apoptosis in Jurkat T cells involves caspase-3 activation, and both lysosomal and mitochondrial destabilisation.

Authors:  J Neuzil; I Svensson; T Weber; C Weber; U T Brunk
Journal:  FEBS Lett       Date:  1999-02-26       Impact factor: 4.124

4.  ATM phosphorylates histone H2AX in response to DNA double-strand breaks.

Authors:  S Burma; B P Chen; M Murphy; A Kurimasa; D J Chen
Journal:  J Biol Chem       Date:  2001-09-24       Impact factor: 5.157

5.  Vitamin E succinate promotes breast cancer tumor dormancy.

Authors:  M P Malafa; L T Neitzel
Journal:  J Surg Res       Date:  2000-09       Impact factor: 2.192

6.  J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential.

Authors:  M Reers; T W Smith; L B Chen
Journal:  Biochemistry       Date:  1991-05-07       Impact factor: 3.162

7.  Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate.

Authors:  Shanta Dhar; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

8.  DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.

Authors:  S Y Shieh; M Ikeda; Y Taya; C Prives
Journal:  Cell       Date:  1997-10-31       Impact factor: 41.582

Review 9.  Cisplatin: mode of cytotoxic action and molecular basis of resistance.

Authors:  Zahid H Siddik
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

Review 10.  Vitamin E succinate and cancer treatment: a vitamin E prototype for selective antitumour activity.

Authors:  J Neuzil
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640
View more
  10 in total

Review 1.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

Review 2.  The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Authors:  Leli Zeng; Pranav Gupta; Yanglu Chen; Enju Wang; Liangnian Ji; Hui Chao; Zhe-Sheng Chen
Journal:  Chem Soc Rev       Date:  2017-10-02       Impact factor: 54.564

Review 3.  The Platin-X series: activation, targeting, and delivery.

Authors:  Uttara Basu; Bhabatosh Banik; Ru Wen; Rakesh K Pathak; Shanta Dhar
Journal:  Dalton Trans       Date:  2016-08-16       Impact factor: 4.390

4.  Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells.

Authors:  Xu Li; Cuixia Gao; Yupei Wu; C-Yan Cheng; Weiliang Xia; Zhiping Zhang
Journal:  J Mater Chem B       Date:  2015-01-02       Impact factor: 6.331

5.  Intratumoral Cancer Chemotherapy with a Carrier-Based Immunogenic Cell-Death Eliciting Platinum (IV) Agent.

Authors:  Chad Groer; Ti Zhang; Ruolin Lu; Shuang Cai; Derek Mull; Aric Huang; Melanie Forrest; Cory Berkland; Daniel Aires; Marcus Laird Forrest
Journal:  Mol Pharm       Date:  2020-10-08       Impact factor: 4.939

6.  Oxamusplatin: a cytotoxic Pt(ii) complex of a nitrogen mustard with resistance to thiol based sequestration displays enhanced selectivity towards cancer.

Authors:  Moumita Maji; Subhendu Karmakar; Arnab Gupta; Arindam Mukherjee
Journal:  Dalton Trans       Date:  2020-02-25       Impact factor: 4.390

7.  Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery.

Authors:  Yao-Rong Zheng; Kogularamanan Suntharalingam; Timothy C Johnstone; Hyunsuk Yoo; Wei Lin; Jamar G Brooks; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2014-06-06       Impact factor: 15.419

8.  Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position.

Authors:  Dina Tolan; Valentina Gandin; Liam Morrison; Ahmed El-Nahas; Cristina Marzano; Diego Montagner; Andrea Erxleben
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

Review 9.  Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands.

Authors:  Xuejiao Li; Yahong Liu; Hongqi Tian
Journal:  Bioinorg Chem Appl       Date:  2018-10-01       Impact factor: 7.778

10.  Comprehensive Vibrational Spectroscopic Investigation of trans,trans,trans-[Pt(N3)2(OH)2(py)2], a Pt(IV) Diazido Anticancer Prodrug Candidate.

Authors:  Robbin R Vernooij; Tanmaya Joshi; Evyenia Shaili; Manja Kubeil; Dominique R T Appadoo; Ekaterina I Izgorodina; Bim Graham; Peter J Sadler; Bayden R Wood; Leone Spiccia
Journal:  Inorg Chem       Date:  2016-06-03       Impact factor: 5.165
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.